Endo moves beyond pain management in Indevus takeover
Endo Pharmaceuticals is expanding beyond its traditional focus on pain medications by acquiring public endocrinology/urology company Indevus Pharmaceuticals for $352mm in cash and a potential $234mm in regulatory earn-outs.
- Specialty Pharmaceuticals
- Controlled Release
- Implantable Devices
- Full Acquisition
- Includes Contract
- Includes Earnout
- Payment Includes Cash for Equity
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.